We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 28, 2021

Serum NfL Association With Progression in Relapsing–Remitting MS Treated With Natalizumab

Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neurology
Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
Neurology 2021 Nov 09;97(19)e1898-e1905, C Bridel, CE Leurs, ZYGJ van Lierop, ZLE van Kempen, I Dekker, HAM Twaalfhoven, B Moraal, F Barkhof, BMJ Uitdehaag, J Killestein, CE Teunissen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading